Repligen Corp. Stock
Repligen Corp. Stock
Repligen Corp. dominated the market today, gaining €12.10 (8.180%).
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Repligen Corp..
With a target price of 182 € there is a slightly positive potential of 13.71% for Repligen Corp. compared to the current price of 160.05 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | 8.180% | -5.556% | -19.532% | -2.569% | -11.754% | -17.879% | - |
| Opko Health Inc. | -0.050% | -0.982% | 29.393% | -16.662% | -19.340% | -68.292% | -46.812% |
| Catalent Inc. | -0.380% | -1.364% | 0.891% | 26.976% | 26.359% | -44.910% | 51.602% |
| Taro Pharmaceutical Industries Ltd | - | 0.000% | 1.546% | 72.807% | 4.787% | -37.953% | -56.546% |
Comments
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Stifel Nicolaus from $165.00 to $207.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at KeyCorp from $210.00 to $220.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $170.00 to $210.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat